NVS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Novartis AG (NVS) is not a strong buy at the moment given the user's long-term investment strategy and beginner level. The current technical indicators show mixed signals, with bearish momentum in the MACD and RSI, and pre-market price dropping by 2.31%. While the company has positive catalysts such as an 8% sales increase and a recent acquisition to enhance its RNA therapeutics pipeline, the financial performance shows declining net income and EPS in the latest quarter. Analysts' ratings are mixed, with some downgrades and modest price target increases. Options data indicates bearish sentiment with a high Put-Call ratio. Considering these factors, holding the stock is the most prudent action for now.
The MACD is bearish with a histogram of -0.933, and RSI is neutral at 35.68. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the pre-market price is down 2.31%. Key support levels are at 160.492 and 157.774, with resistance at 164.891 and 169.289.
8% sales increase in 2025 to $54.5 billion.
Acquisition of Avidity Biosciences for $12 billion, enhancing RNA therapeutics pipeline.
Settlement of Henrietta Lacks case, removing potential legal overhang.
Declining net income (-14.51% YoY) and EPS (-10.71% YoY) in Q4
Bearish sentiment in options data with high Put-Call ratios.
Mixed analyst ratings with recent downgrades and modest price target increases.
In Q4 2025, revenue increased by 2.23% YoY to $13.86 billion, but net income dropped by 14.51% YoY to $2.41 billion. EPS declined by 10.71% YoY to 1.25, and gross margin fell slightly to 74.44%.
Analyst ratings are mixed. Recent upgrades include Deutsche Bank raising the price target to EUR 135 and JPMorgan to CHF 135 with Buy/Overweight ratings. However, DZ Bank downgraded the stock to Hold, and Citi slightly lowered its price target to CHF 132 while maintaining a Buy rating. Analysts see moderate growth potential but note operational challenges.
